Last edition
News about "Dr Chris Chen"
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Dr. Chris Chen | 03/02/2026 | By News Bureau | 192
WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.
Dr. Chris Chen | 29/01/2026 | By News Bureau | 190
WuXi Biologics' Wuxi Facilities Receive MHRA GMP Approval for Ophthalmic Biologic Manufacturing
The UK regulator has certified WuXi Biologics’ DP5 and DPPC sites in Wuxi for commercial production, reinforcing the company’s global GMP-compliant manufacturing capabilities.
Dr. Chris Chen | 13/01/2026 | By News Bureau | 231
WuXi Biologics Extends CRDMO Footprint to Qatar
WuXi Biologics has signed an MoU with the Qatar Free Zones Authority (QFZ) to expand its global footprint into the Middle East. The partnership sets the stage for the company’s first integrated CRDMO centre in the region, strengthening its worldwide research, development, and manufacturing capabilities.
Dr Chris Chen | 02/12/2025 | By Dineshwori | 337
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy